parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in vascular smooth muscle cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 241	0.85
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 15215

SPARCL1 in dopamine neurons, braak+0.19 (p 0.618) → -0.08 (p 0.842)receipt 15223
SPARCL1 in astrocytes, braak-0.88 (p 0.002) → +0.10 (p 0.796)receipt 15222

receipt 15223: SPARCL1 in dopamine neurons, braak

power: full sample +0.13 (p 0.597, n 18), 95% CI -0.36 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.847, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.05 (p 0.840, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.25, sign flips 0; without severely affected donors +0.13 (p 0.597, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SPARCL1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15222: SPARCL1 in astrocytes, braak

power: full sample -0.31 (p 0.218, n 18), 95% CI -0.68 to +0.19. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.32 (p 0.191, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.29 (p 0.250, n 18). could be the mix.
skeptic: leave-one-out range -0.44 to -0.20, sign flips 0; without severely affected donors -0.31 (p 0.218, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SPARCL1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts